DT
CBIO

Diversified Trust’s Crescent Biopharma CBIO Stock Holding History

Diversified Trust’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-139
Closed -$42K – 833
2021
Q1 		$42K Sell
139
-15
-10% -$5.37K ﹤0.01% 752
2020
Q4 		$58K Sell
154
-1
-0.6% -$350 ﹤0.01% 720
2020
Q3 		$48K Hold
155
– – ﹤0.01% 636
2020
Q2 		$58K Buy
+155
New +$43.9K ﹤0.01% 548

Other funds holding CBIO

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Diversified Trust's CBIO Position: Q2 2021 in Review

Diversified Trust sold out of Crescent Biopharma (CBIO) in Q2 2021, closing a stake of 139 shares — an estimated $42K sold.

Diversified Trust first reported a position in CBIO in Q2 2020 and held it in 4 quarters. The position peaked at $58K in Q4 2020. 58 funds tracked by Wall St. Rank hold CBIO as of Q2 2021.

  • Diversified Trust reported no remaining Crescent Biopharma position as of Q2 2021 after selling out during the quarter.
  • Diversified Trust sold 139 Crescent Biopharma shares in Q2 2021, an estimated $42K.
  • Diversified Trust first reported a position in Crescent Biopharma in Q2 2020 and held it in 4 quarters.
  • Diversified Trust's Crescent Biopharma position peaked at $58K in Q4 2020.
  • 58 funds tracked by Wall St. Rank held Crescent Biopharma as of Q2 2021.

Based on Diversified Trust's 13F filing for Q2 2021, filed 20 Jul 2021.